NEW YORK (GenomeWeb) – Thermo Fisher Scientific today announced it has signed an agreement to acquire stem cell research products firm MTI-GlobalStem.
Financial and other terms of the deal were not disclosed.
Gaithersburg, Maryland-based MTI-GlobalStem is a privately held firm specializing in the development and commercialization of tools and reagents for cell transfection, neurobiology, and stem cell research applications. The firm also offers stem cell, differentiated neuron, and large-scale cell culture manufacturing services. Formed when Molecular Transfer bought GlobalStem in 2010, the firm re-branded under its current name in June 2015.
Thermo Fisher said it plans to fold the company into its life sciences solutions segment.
"The addition of MTI-GlobalStem's technology further strengthens Thermo Fisher's leadership in biosciences and provides scientists around the world with access to a wider array of advanced research products designed to help accelerate discovery using cell models," Thermo Fisher VP and General Manager of Cell Biology Amy Butler said in a statement. "Their technology and expertise, combined with Thermo Fisher's global commercial reach, is a strategic fit that enables us to better serve our transfection and stem cell research customers.
This is the latest acquisition for the life sciences research giant. In May, Thermo Fisher announced it would acquire electron microscopy firm FEI Company for $4.2 billion cash.